Truist raises Edwards Lifesciences stock price target on TAVR growth

Edwards Lifesciences posted a strong Q1, with revenue of $1.65 billion beating the $1.60 billion consensus and EPS of $0.78 topping the $0.73 estimate; TAVR sales reached $1.197 billion and TMTT sales were $173 million, both above expectations. Truist nudged its price target to $90 from $89 while keeping a Hold rating, citing continued double-digit TAVR momentum and raised fiscal 2026 guidance. The stock’s premium valuation remains a focus, but the operating beat and improved outlook are supportive.

Analysis

EW is still one of the cleaner ways to own a durable medtech growth compounder, but the market is now paying for a fairly visible path rather than a hidden one. The important read-through is not just that execution is good; it is that the competitive gap versus MDT may widen again before new-product catalysts arrive, because once share loss starts to show up in a procedure franchise it tends to be sticky and self-reinforcing through hospital workflow, physician preference, and training effects.

The second-order issue is valuation asymmetry. At this size, the stock needs either a faster-than-expected inflection in the next growth leg or multiple support from continued rate stability; otherwise, any quarter that is merely in-line could compress the premium quickly. The next 2-3 quarters matter less for earnings revisions than for whether management can prove that the current growth rate is not a peak-ish plateau ahead of the TMTT catalyst window.

From a competitive standpoint, MDT looks like the incremental loser even if the near-term financial damage is still modest. The risk is that share leakage in TAVR becomes a broader signal that interventional cardiovascular franchises can lose compounding advantages faster than consensus models assume, which would pressure sentiment not just in MDT but in adjacent large-cap device names with similar “defend-and-extend” narratives.

The contrarian view is that the market may be underestimating how much of the good news is already embedded in expectations after a strong beat and repeated guide-upward revisions. If TMTT is the real upside call option, investors should be careful not to pay full premium today for a catalyst that is still 12-24 months away and could be partially offset by margin normalization or tougher comps.

Key Decisions for Investors

• Stay long EW, but express it as a tactical hold rather than an aggressive add until the next catalyst cycle; use pullbacks toward 5-7% below current levels to improve entry, with a 6-12 month horizon and downside limited by persistent estimate revisions.
• Initiate a pair trade: long EW / short MDT on a 3-6 month horizon to isolate share-gain versus share-loss in structural valve procedures; target 8-12% relative outperformance if procedure momentum and share capture remain intact.
• For new money, prefer call spreads over outright longs in EW: buy 6-9 month call spreads to capture a continued re-rating while capping premium risk if the stock stalls on valuation concerns.
• If holding MDT, reduce exposure into strength until there is evidence the share-loss trend is stabilizing; the risk/reward is unfavorable if the market begins to price in a longer competitive reset.